PT1556025E - Da rigidez das art?rias relacionada com o envelhecimento - Google Patents

Da rigidez das art?rias relacionada com o envelhecimento Download PDF

Info

Publication number
PT1556025E
PT1556025E PT03790959T PT03790959T PT1556025E PT 1556025 E PT1556025 E PT 1556025E PT 03790959 T PT03790959 T PT 03790959T PT 03790959 T PT03790959 T PT 03790959T PT 1556025 E PT1556025 E PT 1556025E
Authority
PT
Portugal
Prior art keywords
vitamin
left ventricular
preventing
arteries
stroke
Prior art date
Application number
PT03790959T
Other languages
English (en)
Inventor
Cees Vitak Bv Vermeer
Original Assignee
Nattopharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1556025(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nattopharma Asa filed Critical Nattopharma Asa
Publication of PT1556025E publication Critical patent/PT1556025E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT03790959T 2002-08-30 2003-09-01 Da rigidez das art?rias relacionada com o envelhecimento PT1556025E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220182.0A GB0220182D0 (en) 2002-08-30 2002-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
PT1556025E true PT1556025E (pt) 2011-05-11

Family

ID=9943229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03790959T PT1556025E (pt) 2002-08-30 2003-09-01 Da rigidez das art?rias relacionada com o envelhecimento

Country Status (11)

Country Link
US (3) US20060166948A1 (pt)
EP (1) EP1556025B1 (pt)
AT (1) ATE499094T1 (pt)
AU (1) AU2003264150A1 (pt)
DE (1) DE60336161D1 (pt)
DK (1) DK1556025T3 (pt)
ES (1) ES2361740T3 (pt)
GB (1) GB0220182D0 (pt)
PT (1) PT1556025E (pt)
SI (1) SI1556025T1 (pt)
WO (1) WO2004019923A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060191026A1 (en) 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
WO2005027832A2 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Edta containing compositions and uses thereof
BE1016566A4 (fr) * 2004-05-25 2007-02-06 Psaltopoulos Emmanuel Procede pour fournir les besoins quotidiens de l'etre humain en calcium (ca), en vitamine "d" et en vitamine "k" sous forme de pilule a croquer ou a avaler.
WO2006113479A2 (en) 2005-04-15 2006-10-26 Albert Einstein College Of Medicine Of Yeshiva University Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
PL1728507T3 (pl) * 2005-06-03 2011-09-30 Nattopharma Asa Zastosowanie witaminy K w celu cofnięcia zwapnienia naczyń krwionośnych
US8923972B2 (en) 2005-07-25 2014-12-30 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US9642726B2 (en) 2005-07-25 2017-05-09 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9592136B2 (en) 2005-07-25 2017-03-14 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9125732B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
ITRM20050521A1 (it) * 2005-10-21 2007-04-22 Opocrin Spa Composizione a base di vitamine k e d per la prevenzione e il trattamento dell'osteoporosi.
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
PL2046312T3 (pl) 2006-07-14 2021-02-08 Kaydence Pharma As Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
FR2916354B1 (fr) * 2007-05-25 2009-08-07 Univ Picardie Jules Verne Etab Composition pharmaceutique pour inhiber la calcification vasculaire.
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
US20090053366A1 (en) * 2007-08-21 2009-02-26 Marni Markell Hurwitz Refreshment system having effervescent supplement tablets
WO2009108297A2 (en) * 2008-02-25 2009-09-03 Nephrian, Inc. Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
US20100331286A1 (en) * 2008-02-25 2010-12-30 Ray Chow Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
ES2725524T3 (es) 2008-09-26 2019-09-24 Vascular Dynamics Inc Dispositivos y métodos para controlar la presión arterial
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
FR2949044B1 (fr) 2009-08-12 2021-05-07 Expanscience Lab Composition comprenant une fraction d'insaponifiable
EP2493314B1 (en) 2009-10-30 2020-04-08 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
US9333228B2 (en) * 2010-06-01 2016-05-10 Top Doctors Labs, Llc Nutritional supplement for recovery, repair, and maintenance
US20130237610A1 (en) * 2010-11-01 2013-09-12 Dilip Mehta Dynamic balancing of autonomic nervous system through vitamin mk-7
EP2651250A1 (en) * 2010-12-17 2013-10-23 VitaK B.V. Use of vitamin k for weight maintenance and weight control
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
EP2696865B1 (en) 2011-04-13 2016-12-21 Thermolife International, LLC N-acetyl beta alanine methods of use
EP2709460A1 (en) * 2011-05-20 2014-03-26 Friesland Brands B.V. Composition comprising vitamin k2
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
EP2886129A1 (en) * 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
ITPD20140287A1 (it) * 2014-10-30 2016-04-30 Fusaro Maria K-pharma
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
BR112020019832A2 (pt) * 2018-03-30 2021-01-05 Kaydence Pharma As Métodos para melhorar função cardiovascular, elasticidade, velocidade de onda de pulso ou disfunção endotelial, reduzir rigidez arterial e/ou para reverter calcificação de um vaso sanguíneo em um mamífero e para aumentar produção de óxido nítrico endotelial em um sujeito, e, kit
EP3937916A1 (en) * 2019-03-11 2022-01-19 Kaydence Pharma AS Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k
CN110122866A (zh) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 一种慢性肾脏病血管钙化的特殊医学用途食品及制备方法
US20240082198A1 (en) * 2020-10-01 2024-03-14 Emergent Product Development Gaithersburg Inc. Stabilized alkyl nitrite compositions
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
US20230060177A1 (en) * 2021-08-19 2023-03-02 Imam Abdulrahman Bin Faisal University Method for treating athletes subject to pathological cardiac hypertrophy by administering nigella sativa

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3949098A (en) * 1974-06-05 1976-04-06 Nabisco, Inc. Nutritious orange drink concentrate, process and drink resultant therefrom
GB8523338D0 (en) * 1985-09-20 1985-10-23 Kreitzman S N Treatment of obesity
US5180747A (en) * 1989-02-28 1993-01-19 Nisshin Flour Milling Co., Ltd. Stabilized fat-soluble vitamin compositions
JPH06312950A (ja) * 1993-03-01 1994-11-08 Eezai Kagaku Kk キノン誘導体の製造法および中間体
US5590649A (en) * 1994-04-15 1997-01-07 Vital Insite, Inc. Apparatus and method for measuring an induced perturbation to determine blood pressure
DE69501421T2 (de) 1994-04-28 1998-04-23 Eisai Co Ltd Hematetrenome Derivat als antiarteriosklerotisches Mittel
JP3860849B2 (ja) * 1994-04-28 2006-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗動脈硬化治療剤
GB9600604D0 (en) * 1996-01-12 1996-03-13 Boots Co Plc Composition
GB9713620D0 (en) 1997-06-28 1997-09-03 Boots Co Plc Composition
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
KR20020016833A (ko) * 1999-06-15 2002-03-06 뉴트리-로직스, 인크. 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
DE19955607A1 (de) * 1999-11-19 2001-06-07 November Ag Molekulare Medizin Medikament oder aufeinander abgestimmte Kombination von Medikamenten
PT1153548E (pt) 2000-05-12 2007-08-08 Nattopharma Asa Produto alimentar contendo vitamina k
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003013420A2 (en) 2001-08-03 2003-02-20 Vitak Bv Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
PL1728507T3 (pl) 2005-06-03 2011-09-30 Nattopharma Asa Zastosowanie witaminy K w celu cofnięcia zwapnienia naczyń krwionośnych

Also Published As

Publication number Publication date
SI1556025T1 (sl) 2011-07-29
GB0220182D0 (en) 2002-10-09
US20060166948A1 (en) 2006-07-27
US9364447B2 (en) 2016-06-14
WO2004019923A1 (en) 2004-03-11
AU2003264150A1 (en) 2004-03-19
DE60336161D1 (de) 2011-04-07
US20160250160A1 (en) 2016-09-01
US20050261257A1 (en) 2005-11-24
DK1556025T3 (da) 2011-05-23
EP1556025A1 (en) 2005-07-27
EP1556025B1 (en) 2011-02-23
ES2361740T3 (es) 2011-06-21
ATE499094T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
PT1556025E (pt) Da rigidez das art?rias relacionada com o envelhecimento
PT1728507E (pt) Utiliza??o de vitamina k para inverter a calcifica??o dos vasos sangu?neos
Aronow et al. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation
Santa‐Cruz et al. Aortic counterpulsation: a review of the hemodynamic effects and indications for use
Radke et al. Anomalous origin of the right coronary artery: preoperative and postoperative hemodynamics
NO20045557L (no) Kombinasjon av en DPP IV inhibitor og en kardiovaskulaer forbindelse
Ennabli et al. Morbidity and mortality of coronary artery surgery after the age of 70 years
IL166493A0 (en) Acylamino-substituted heteroaromatic compounds andtheir use as pharmaceuticals
JP2015512387A5 (pt)
WO2003015695B1 (en) Canine cardiac diet
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
Ceyhan et al. Myocardial infarction following a bee sting
Tio et al. Ventricular septal rupture caused by myocardial bridging
WO2022240379A3 (en) A stable pharmaceutical composition comprising selexipag
DK1458381T3 (da) Triazoler som oxytocinantagonister
PT1150963E (pt) 4-amino-2-ariltetra-hidroquinazolinas substituidas sua preparacao sua utilizacao e composicoes farmaceuticas que as contem
Patanè et al. Acute myocardial infarction and Kounis syndrome
Patanè et al. Paroxysmal Mobitz type-I atrioventricular block Luciani–Wenckebach conduction, acute myocardial infarction and severe three vessels coronary artery disease
Treistman et al. Saphenous vein bypass from the aorta to the anterior interventricular vein
Prasad et al. Modified supra-arterial myotomy for intermittent coronary obstruction by myocardial bridges
EK et al. Long-term effect of isosorbide dinitrate and nifedipine, singly and in association, in patients with chronic heart failure
JP2017530954A5 (pt)
Teixeira Filho et al. Right ventricular aneurysm following right ventricular infarction
Bidoggia et al. Beneficial effects of isosorbide-5-mononitrate on exercise performance in patients with chronic stable angina pectoris
Guo et al. Coronary artery spasm: a rare but important cause of postoperative myocardial infarction